Tufts Medical Center
Biewend Building, 3rd Floor
800 Washington St., #238
Boston, MA 02111
Phone #: 617-636-7010
Taylor LE, Foont JA, DeLong AK, Wurcel, A, Linas BP, Chapman SC, Maynard MA, Cu-Uvin S, Mayer KH. The Spectrum of Undiagnosed Hepatitis C Virus Infection in a U.S. HIV Clinic. AIDS Patient Care and STDS. Volume 28, Number 1, 2014.
Wurcel,AG. To whom shall I tell my grief? Am J Kidney Dis. November 2013;62(5):xxv-xxvi.
Sung S*, Wurcel AG*, Whittier S, Kulas K, Kramer LD, Flam R, et al. Powassan meningoencephalitis, New York City, USA. Emerg Infect Dis [Internet]. 2013 Sep (*co-first authors).
McNairy M, Wurcel A, Huang F, Daly J. Health care workers in Africa access a broad range of topics using evidence-based online medical information. Global Public Health Journal May 2012. PMID #22621407
Ancuta P, Kamat A, Kunstman KJ, Kim EY, Autissier P, Wurcel A, Zaman T, Stone D, Mefford M, Morgello S, Singer EJ, Wolinsky SM, Gabuzda D. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS ONE. 2008 Jun 25;3(6):e2516.
Corey KE, Ross AS, Wurcel A, Schulze Zur Wiesch J, Kim AY, Lauer GM, Chung RT. Outcomes and treatment of acute hepatitis C virus infection in a United States population. Clin Gastroenterol Hepatol. 2006 Oct; 4(10):1278-82.
Gasnik LB, Wurcel AG, Kotolff RM, Lautenbauch E, Blumberg EA. Low Prevalence of prior streptococcus pneumoniae vaccination among potential lung transplant candidates. Chest 2006 Jul; 130 (1)218-21.
McGovern BH, Wurcel A, Kim AY, Schulze zur Wiesch J, Bica I, Zaman MT, Timm J, Walker BD, Lauer GM. Acute hepatitis C virus infection in incarcerated injection drug users. Clin Infect Dis. 2006 Jun 15;42(12):1663-70. Epub 2006 May 11.
Ancuta P, Autissier P, Wurcel A, Zaman T, Stone D, Gabuzda D. CD16+ monocyte-derived macrophages activate resting T cells for HIV infection by producing CCR3 and CCR4 ligands. J Immunol. 2006 May 15;176(10):5760-71.
Frahm N, Kiepiela P, Adams S, Linde CH, Hewitt HS, Sango K, Feeney ME, Addo MM, Lichterfeld M, Lahaie MP, Pae E, Wurcel AG, Roach T, St John MA, Altfeld M, Marincola FM, Moore C, Mallal S, Carrington M, Heckerman D, Allen TM, Mullins JI, Korber BT, Goulder PJ, Walker BD, Brander C. Control of human Immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol. 2005 Dec 20
Wurcel A, Zaman MT, Zhen S, Stone DR. Acceptance of HIV Antibody Testing Among Inpatients and Outpatients at a Public Health Hospital: A Study of Rapid versus Standard Testing. AIDS Patient Care STDS. 2005 Aug;19(8):499-505.
McGovern B, Fiore J, Wurcel A, Taglienti P, Bradley M, Galvin S, Libone G, Ramsey J, Molinaro-Gudas V, Drewniak S, Amick C, Andalkar A, Scheft H, Bica I. Delivering therapy for hepatitis C virus infection to incarcerated, HIV-seropositive patients. Clin Infectious Diseases. 2005 Jul 1;41 Suppl 1:S56-62.
Gandhi RT, Wurcel A, Lee H, McGovern B, Shopis J, Geary M, Sivamurthy R, Sax PE, Ukomadu C. Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J Infect Dis. 2005 May 1;191(9):1435-41. Epub 2005 Mar 28.
Gandhi, RT, Wurcel A, Toner S, McGovern B, Lee H, Shopis J, Corcoran CP, Ukamodu C, Sax P. “Low Prevalence of Ongoing Hepatitis B Viremia in HIV+ Individuals with Isolated Antibody to Hepatitis B Core Antigen.” J Acquir Immune Defic Syndr. 2003 Dec 1;34(4):439-41.
Gandhi, RT, Wurcel A, Hirsch M, Johnston MP, Rosenberg E, Walker, B. Progressive Reversion of Human Immunodeficiency Virus (HIV)-1 Resistance Mutations In vivo Following Transmission of a Multiply Drug Resistant Virus. Clinical Infectious Diseases 2003 Dec.15;37(12):1693-8.
Gandhi, RT, Wurcel A, Lee H, McGovern B, Boczanowski M, Gerwin R, Corcoran CO, Szczepiorkowski Z, Toner S, Cohen DE, Ukomadu C. Isolated Antibody to Hepatitis B Core Antigen in Human Immunodeficiency Virus (HIV)-1-infected Individuals. Clinical Infectious Diseases, 2003 Jun 15;36(12):1602-5.
Day CL, Lauer GM, Robbins GK, McGovern B, Wurcel AG, Gandhi RT, Walker BD. Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved Hepatitis C virus infection. Journal of Virology. 2002 Dec.; 76(24):12584-95.
Stone DR, Corcoran, C, Wurcel A, McGovern B, Quirk J, Brewer A, Sutton L, D’Aquila RT. Antiretroviral Drug Resistance in Antiretroviral Naïve Prisoners. Clinical Infectious Diseases. 200:2 35. October 1, 2002. PP 883-886.
Dr. Wurcel completed her undergraduate education at Tufts University. She is a graduate of University of Pennsylvania School of Medicine and received a Masters in Clinical Research from the Sacker School of Graduate Biomedical Sciences at Tufts University School of Medicine. In addition to her faculty position in the Department of Geographic Medicine and Infectious Diseases, she is an Assistant Professor in the Department of Community Medicine and Public Health at the Tufts University School of Medicine. She has a weekly HIV/HCV co-infection clinic and also treats people with HIV and HCV mono-infection. Once a month in her co-infection clinic, she sees patients with Dr. Hannah Lee of the GI department.
Her research interests include treatment of Hepatitis C Virus in people considered "tough to treat" including people who inject drugs (PWID), people in the criminal justice system and people with HIV (PLWH). She is the co-investigator of the Tufts REACTs Study (Responds to the Epidemic of hepatitis C Together), a mixed methods project aimed at assessing HCV treatment readiness in young PWID. This study was awarded funding through the Tufts Institute for Innovation in 2015. She is the PI on a Bristol-Myers Squibb study in a clinical trial of HIV medication called an HDAC Inhibitor. Tufts Medical Center is the only hospital in Boston to offer this clinical trial. She also has funding to conduction quality improvement studies on increasing annual HCV antibody testing in PLWH who were Hepatitis C Antibody negative on entry into HIV care.
Dr. Wurcel was recently named to the Tufts Institute of Innovation Affiliates. Affiliates are active members of the TII community
they have access to TII lab space, are invited to participate in TII Project Review meetings, and can extend their three-year appointment after its expiration by securing external funding for their projects.